Ani Pharmaceuticals INC Form 4 insider transactions

ANI Pharmaceuticals Director Antonio R. Pera sold 5,421 shares of common stock for approximately $486,300, reducing his direct beneficial ownership.

ANI Pharmaceuticals Director Matthew J. Leonard sold 6,937 shares of common stock for a weighted average price of $88.17 per share, a transaction executed under a Rule 10b5-1 plan.

ANI Pharmaceuticals Director Patrick D. Walsh filed a Form 4 indicating a future sale of 9,000 common shares at $89.05 per share, executed under a Rule 10b5-1 plan.

A key executive at ANI Pharmaceuticals, Muthusamy Shanmugam, sold 100,000 shares of common stock for approximately $8.8 million over two days in August 2025.

ANI Pharmaceuticals' SVP of Corporate Development & Strategy, Chad Gassert, sold 20,000 shares of common stock for approximately $1.74 million under a pre-arranged trading plan.

ANI Pharmaceuticals' SVP, Thomas Rowland, sold 4,975 shares of common stock for approximately $426,400.

ANI Pharmaceuticals' President & CEO, Nikhil Lalwani, sold 56,960 shares of common stock for a weighted average price of $85.93 per share.

ANI Pharmaceuticals SVP Ori Gutwerg reported a pre-planned sale of 5,873 common shares scheduled for August 12, 2025, at an expected weighted average price of $86.53 per share.

ANI Pharmaceuticals' Senior VP, General Counsel & Secretary, Meredith Cook, sold 400 shares of common stock for $88.87 per share under a pre-arranged 10b5-1 trading plan.

ANI Pharmaceuticals' SVP & CFO, Stephen P. Carey, exercised stock options and subsequently sold 50,000 shares of common stock for a significant profit.

ANI Pharmaceuticals Director Thomas Haughey sold 19,341 shares of common stock for approximately $1.66 million, executed under a pre-planned Rule 10b5-1 program.

Meredith Cook, SR. VP, General Counsel & Secretary of ANI Pharmaceuticals Inc., withheld 2,071 shares of common stock valued at $66.3 per share for tax purposes related to restricted stock vesting.

Meredith Cook, SR. VP, General Counsel & Secretary of ANI Pharmaceuticals Inc., reported the future sale of 400 shares of common stock on July 14, 2025, executed under a pre-established Rule 10b5-1 trading plan.

Meredith Cook, Senior Vice President, General Counsel & Secretary of ANI Pharmaceuticals Inc. (ANIP), sold 400 shares of common stock for $61.37 per share, as part of a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Inc. Director Thomas Haughey has been granted 4,336 shares of common stock as a restricted stock award, vesting in May 2026.

ANI Pharmaceuticals Inc. Director Matthew J. Leonard received a grant of 4,336 shares of common stock as a restricted stock award, which is set to vest in May 2026.

Antonio R. Pera, a Director at ANI Pharmaceuticals, Inc., has been granted 4,336 shares of common stock as a restricted stock award, set to vest in May 2026.

Renee P. Tannenbaum, a Director at ANI Pharmaceuticals Inc., was granted 4,336 shares of common stock as a restricted stock award, vesting in May 2026.

Jeanne Thoma, a Director at ANI Pharmaceuticals Inc., received a restricted stock award of 4,336 common shares, increasing her beneficial ownership to 44,945 shares, with vesting scheduled for May 22, 2026.

ANI Pharmaceuticals Director Patrick D. Walsh received a restricted stock award of 4,336 shares of common stock, increasing his total beneficial ownership to 79,048 shares.

Ori Gutwerg, SVP, Generics at ANI Pharmaceuticals, sold 881 shares of common stock at an average price of $60.07 on May 15, 2025.

Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, sold 4,000 shares of common stock at $60.45 per share on May 14, 2025.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, sold 400 shares of common stock on May 13, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Muthusamy Shanmugam, a Director and Officer of ANI Pharmaceuticals, sold 700 shares of common stock at an average price of $76.83 on May 9, 2025, under a pre-arranged trading plan.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, sold 400 shares of common stock at $68.96 per share on April 14, 2025, under a pre-arranged 10b5-1 trading plan.

Nikhil Lalwani, CEO of ANI Pharmaceuticals, disposed of shares to cover tax obligations related to the vesting of restricted stock.

Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals, reports the withholding of shares for tax purposes related to the vesting of restricted stock.

Krista Davis, SVP, CHIEF HR OFFICER of ANI Pharmaceuticals, sold 1,866 shares of common stock at $65 per share on March 19, 2025, according to a Form 4 filing.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, sold 400 shares of common stock on March 13, 2025, at a price of $63.33 per share.

Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, reports a transaction involving the withholding of shares for tax purposes related to vesting restricted stock.